Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
2.530
+0.110 (4.55%)
At close: May 12, 2025, 4:00 PM
2.600
+0.070 (2.77%)
After-hours: May 12, 2025, 6:50 PM EDT
Vigil Neuroscience Employees
Vigil Neuroscience had 69 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,256,942
Market Cap
118.08M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69 | 0 | - |
Dec 31, 2023 | 69 | 13 | 23.21% |
Dec 31, 2022 | 56 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VIGL News
- 5 days ago - Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates - GlobeNewsWire
- 5 weeks ago - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference - GlobeNewsWire
- 2 months ago - Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates - GlobeNewsWire
- 2 months ago - Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewsWire
- 3 months ago - Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - Benzinga
- 3 months ago - Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease - GlobeNewsWire
- 4 months ago - Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewsWire